Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. (2014)


No abstract provided

Bibliographic Information

Digital Object Identifier:

PubMed Identifier: 24924991

Publication URI:

Type: Journal Article/Review

Volume: 15

Parent Publication: The Lancet. Oncology

Issue: 8

ISSN: 1470-2045